Efficacy of the ATl-angiotensin receptor blocker eprosartan in patients with arterial hypertension in the different functional state of the renin-angiotensin-aldesterone system

The purpose of the study was to examine the effects of the AT₁-angiotensin receptor blocker eprosartan (Teveten, “Solvay Pharma”) on the level of blood pressure (BP) as compared with the functional state of the renin-angiotensin-aldosterone system in patients with arterial hypertension (AH) of different genesis. Eprosartan was given in a daily dose of 600 mg for 8 weeks. If there was no normalization of BP or achievement of its target level, the therapy was supplemented by hypothiazide in a dose of 25 mg. Thirty-thirty hypertensive patients with symptomatic BP of renal genesis. Clinical BP measurements indicated that 8-week eprosartan therapy caused a 10 mm Hg or more reduction in systolic BP in 26 (78,8%) patients, systolic BP becoming normal (less than 140 mm Hg) in 21 (63,6%) patients and diastolic BP (less than 90 mm Hg) in 23 (69,7%). Analyzing the antihypertensive effect of eprosartan in relation to the severity of AH has established that eprosartan significantly lowers BP in the groups of mild [143±3,42/86±4,25 mm Hg before treatment, 118±2,56/75±3,54 mm Hg (p<0,001) after treatment], moderate [151±2,9/94±2,81 mm Hg before treatment, 128±3,24/81±2,14 mm Hg (p<0,001) after treatment], and severe [199±3,1/116±2,51 mm Hg before treatment, l63±3,32/95±3,62 mm Hg (p<0,001) after treatment] forms of AH. At the same time the best effect was achieved in patients with mild and moderate forms of AH. Examining the renin-angiotensin-aldosterone system during therapy with eprosartan as compared to its antihypertensive effect has revealed a significant decrease in BP after 8-week therapy both in patients with normal and higher activity of renin (a decrease in systolic BP by 30.0±4,97 mm Hg and in diastolic BP by 16,8±7,8 mm Hg, p<0,001) and in diastolic BP by 16,8±7,8 mmHg, p < 0,001) and in those with low-renin form of AHby 14,2±2,34 mm Hg, p<0,001).The findings suggest that AT j-angiotensin receptor blockers are beneficial not only in hypertensive patients with high and normal ARP but also in those with ARP, which expands the field of their clinical use.

arterial hypertension, AT₁-angiotensin receptor blockers, renin-angiotensin-aldosterone system

1. Laragb JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use off renin and aldosterone profiles.Am J Med I973; 55: 261-74.

2. Jackson TK, Garrison JC. The Pharmacological Basis of Therapeut. Eds J Hardman et al. 9-th ed. New York 1996; 733-58.

3. Goodfriend ThL1 Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. Drag Therapy 1966; 334 (25):

4. Weber MA Interrupting the RAS: the role of iACE and angiotensin 11 receptor antagonists in the treatment of hypertension. Am J Hypertens 1999 Dec; 12 (12Pt3): 189S-194S.

5. B& Levine. Effects of Eprosartan and Enalaprilin the Treqatment of Black Hypertensive Patients: Subgroup Analisis of a 26-Week, Double-blind, Multicentre Study. Current Med Res. Opinion 1999; (I): 25-32.

6. Levine B. Effects of eprosartan and enalaprilin the treatment of black, hypertensive patients: subgroup analisis of a 26-week, double-blind, midticentre study. Current Medical Reseach and Opinion. 1999; 15 (I): 25-32.

7. Gavras and Gavras H Effects of eprosartan versus enalapril in hypertensive hatients on the renin-angiotensin-aldosterone system and parameters: results from a 26-week, double-blind, multicentre study. Current Medical Reseach and Opinion. 1999; 15 (I): 15-24